Oxybuprocaine (also known as Benoxinate) is a local anesthetic, which is used especially in ophthalmology and otolaryngology. Oxybuprocaine binds to sodium channels and reversibly stabilizes the neuronal membrane which decreases its permeability to sodium ions.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Buprenorphine | Oxybuprocaine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Oxybuprocaine. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Oxybuprocaine. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Oxybuprocaine. |
| Hydrocodone | Oxybuprocaine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Oxybuprocaine. |
| Magnesium sulfate | The therapeutic efficacy of Oxybuprocaine can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Oxybuprocaine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Oxybuprocaine may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Oxybuprocaine. |
| Mirtazapine | Oxybuprocaine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Oxybuprocaine. |
| Orphenadrine | Oxybuprocaine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Oxybuprocaine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Oxybuprocaine. |
| Pramipexole | Oxybuprocaine may increase the sedative activities of Pramipexole. |
| Ropinirole | Oxybuprocaine may increase the sedative activities of Ropinirole. |
| Rotigotine | Oxybuprocaine may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Oxybuprocaine. |
| Sodium oxybate | Oxybuprocaine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | Oxybuprocaine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Oxybuprocaine. |
| Thalidomide | Oxybuprocaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Oxybuprocaine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Hyaluronidase (ovine) | Hyaluronidase (ovine) can cause an increase in the absorption of Oxybuprocaine resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Hyaluronidase (human recombinant) | Hyaluronidase (human recombinant) can cause an increase in the absorption of Oxybuprocaine resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Hyaluronidase | Hyaluronidase can cause an increase in the absorption of Oxybuprocaine resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Oxybuprocaine. |
| Pegvisomant | Pegvisomant may increase the neuromuscular blocking activities of Oxybuprocaine. |
| Mefloquine | The risk or severity of methemoglobinemia can be increased when Mefloquine is combined with Oxybuprocaine. |
| Tacrine | Tacrine may increase the neuromuscular blocking activities of Oxybuprocaine. |
| Sulpiride | Sulpiride may increase the neuromuscular blocking activities of Oxybuprocaine. |
| Profenamine | Profenamine may increase the neuromuscular blocking activities of Oxybuprocaine. |
| Chlorpromazine | Chlorpromazine may increase the neuromuscular blocking activities of Oxybuprocaine. |
| Gallamine triethiodide | Gallamine triethiodide may increase the neuromuscular blocking activities of Oxybuprocaine. |
| Triflupromazine | Triflupromazine may increase the neuromuscular blocking activities of Oxybuprocaine. |
| Cisplatin | The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Oxybuprocaine. |
| Cinchocaine | The risk or severity of methemoglobinemia can be increased when Cinchocaine is combined with Oxybuprocaine. |
| Pyridostigmine | Pyridostigmine may increase the neuromuscular blocking activities of Oxybuprocaine. |
| Nizatidine | Nizatidine may increase the neuromuscular blocking activities of Oxybuprocaine. |
| Galantamine | Galantamine may increase the neuromuscular blocking activities of Oxybuprocaine. |
| Isoflurophate | Isoflurophate may increase the neuromuscular blocking activities of Oxybuprocaine. |
| Diethylcarbamazine | Diethylcarbamazine may increase the neuromuscular blocking activities of Oxybuprocaine. |
| Procaine | The risk or severity of methemoglobinemia can be increased when Procaine is combined with Oxybuprocaine. |
| Minaprine | Minaprine may increase the neuromuscular blocking activities of Oxybuprocaine. |
| Donepezil | Donepezil may increase the neuromuscular blocking activities of Oxybuprocaine. |
| Terbutaline | Terbutaline may increase the neuromuscular blocking activities of Oxybuprocaine. |
| Mechlorethamine | The risk or severity of methemoglobinemia can be increased when Mechlorethamine is combined with Oxybuprocaine. |
| Hexafluronium | Hexafluronium may increase the neuromuscular blocking activities of Oxybuprocaine. |
| Demecarium | Demecarium may increase the neuromuscular blocking activities of Oxybuprocaine. |
| Physostigmine | Physostigmine may increase the neuromuscular blocking activities of Oxybuprocaine. |
| Rivastigmine | Rivastigmine may increase the neuromuscular blocking activities of Oxybuprocaine. |
| Edrophonium | Edrophonium may increase the neuromuscular blocking activities of Oxybuprocaine. |
| Procainamide | Procainamide may increase the neuromuscular blocking activities of Oxybuprocaine. |
| Memantine | Memantine may increase the neuromuscular blocking activities of Oxybuprocaine. |
| Ambenonium | Ambenonium may increase the neuromuscular blocking activities of Oxybuprocaine. |
| Tubocurarine | Tubocurarine may increase the neuromuscular blocking activities of Oxybuprocaine. |
| Ketamine | Ketamine may increase the neuromuscular blocking activities of Oxybuprocaine. |
| Decamethonium | Decamethonium may increase the neuromuscular blocking activities of Oxybuprocaine. |
| Pancuronium | Pancuronium may increase the neuromuscular blocking activities of Oxybuprocaine. |
| Pipecuronium | Pipecuronium may increase the neuromuscular blocking activities of Oxybuprocaine. |
| Ginkgo biloba | Ginkgo biloba may increase the neuromuscular blocking activities of Oxybuprocaine. |
| Neostigmine | Neostigmine may increase the neuromuscular blocking activities of Oxybuprocaine. |
| Bambuterol | Bambuterol may increase the neuromuscular blocking activities of Oxybuprocaine. |
| 1,10-Phenanthroline | 1,10-Phenanthroline may increase the neuromuscular blocking activities of Oxybuprocaine. |
| Methylphosphinic Acid | Methylphosphinic Acid may increase the neuromuscular blocking activities of Oxybuprocaine. |
| Thiotepa | The risk or severity of methemoglobinemia can be increased when Thiotepa is combined with Oxybuprocaine. |
| Huperzine A | Huperzine A may increase the neuromuscular blocking activities of Oxybuprocaine. |
| Phenserine | Phenserine may increase the neuromuscular blocking activities of Oxybuprocaine. |
| Regramostim | Regramostim may increase the neuromuscular blocking activities of Oxybuprocaine. |
| Aprotinin | Aprotinin may increase the neuromuscular blocking activities of Oxybuprocaine. |
| Betaine | Betaine may increase the neuromuscular blocking activities of Oxybuprocaine. |
| Capsaicin | The risk or severity of methemoglobinemia can be increased when Oxybuprocaine is combined with Capsaicin. |
| Coumaphos | Coumaphos may increase the neuromuscular blocking activities of Oxybuprocaine. |
| Dichlorvos | Dichlorvos may increase the neuromuscular blocking activities of Oxybuprocaine. |
| Fenthion | Fenthion may increase the neuromuscular blocking activities of Oxybuprocaine. |
| Metrifonate | Metrifonate may increase the neuromuscular blocking activities of Oxybuprocaine. |
| Acotiamide | Acotiamide may increase the neuromuscular blocking activities of Oxybuprocaine. |
| Methanesulfonyl Fluoride | Methanesulfonyl Fluoride may increase the neuromuscular blocking activities of Oxybuprocaine. |
| Paraoxon | Paraoxon may increase the neuromuscular blocking activities of Oxybuprocaine. |
| Tyrothricin | The risk or severity of methemoglobinemia can be increased when Tyrothricin is combined with Oxybuprocaine. |
| Ipidacrine | Ipidacrine may increase the neuromuscular blocking activities of Oxybuprocaine. |
| Distigmine | Distigmine may increase the neuromuscular blocking activities of Oxybuprocaine. |
| Tretamine | The risk or severity of methemoglobinemia can be increased when Tretamine is combined with Oxybuprocaine. |
| Posiphen | Posiphen may increase the neuromuscular blocking activities of Oxybuprocaine. |
| Ethanol | Oxybuprocaine may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Oxybuprocaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Oxybuprocaine. |
| Fluvoxamine | The risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Fluvoxamine. |
| Citalopram | The risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Citalopram. |
| Duloxetine | The risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Duloxetine. |
| Trazodone | The risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Trazodone. |
| Paroxetine | The risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Paroxetine. |
| Sertraline | The risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Sertraline. |
| Sibutramine | The risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Sibutramine. |
| Nefazodone | The risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Nefazodone. |
| Escitalopram | The risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Escitalopram. |
| Zimelidine | The risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Zimelidine. |
| Dapoxetine | The risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Dapoxetine. |
| Milnacipran | The risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Milnacipran. |